Methods and compositions for treating and diagnosing pancreatic cancers
The application relates to methods based on modulating mammalian intestinal and/or pancreatic microbiota and related probiotic, prebiotic, and anti-bacterial compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.
1. A method for treating a pancreatic cancer or pancreatic tumor in a subject in need thereof, said method comprising administering to the subject an effective amount of one or more probiotic compositions comprising one or more strains of bacteria from species Akkermansia muciniphila and one or more strains of bacteria from species Lactobacillus reuteri and further comprising administering a programmed cell death protein 1 (PD-1) inhibitor.
2. The method of claim 1 , said method further comprising administering to the subject an effective amount of (i) one or more probiotic compositions comprising one or more strains of bacteria from one or more species selected from the group consisting of Bifidobacterium pseudolongum, Faecalibacterium prausnitzii , and Propionibacterium acnes , wherein said one or more probiotic compositions are administered to the pancreatic microbiota of the subject, and/or (ii) one or more probiotic compositions comprising one or more strains of bacteria from one or more species selected from the group consisting of Bacteroides eggerthii, Blautia producta, Candidatus arthromitus, Eubacterium biforme, Lactobacillus ruminis , and TM7, wherein said one or more compositions are administered to the gastrointestinal (GI) microbiota of the subject, and/or (iii) one or more compounds and/or compositions which inhibit growth and/or activity of one or more strains of bacteria from one or more species selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium pseudolongum, Elizabethkingia meningoseptica, Mucispirillum schaedleri, Streptococcus anginosus , and Veillonella dispar in the pancreatic microbiota of the subject, and/or (iv) one or more compounds and/or compositions which inhibit growth and/or activity of one or more strains of bacteria from one or more species selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium animalis, Bifidobacterium pseudolongum, Desulfovibrio D168 , Elizabethkingia meningoseptica, Escherichia coli, Mucispirilhum schaedleri, Oxalobacter formigenes, Parabacteroides distasoni, Peptostreptococcus anaerobius, Prevotella melaninogenica, Prevotella stercorea, Pyramidobacter piscolens, Rothia mucilaginosa, Streptococcus anginosus , and Veillonella dispar in the gastrointestinal (GI) microbiota of the subject.
3. The method of claim 1 , wherein said one or more probiotic composition(s) comprise live bacterial cells, spores, and/or conditionally lethal bacterial cells of Akkermansia muciniphila and Lactobacillus reuteri.
4. The method of claim 1 , said method further comprising administering to the subject an effective amount of one or more compounds and/or compositions, wherein said compounds and/or compositions (i) inhibit growth and/or activity of one or more strains of bacteria from one or more species selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium pseudolongum, Elizabethkingia meningoseptica, Mucispirillum schaedleri Streptococcus anginosus , and Veillonella dispar in the pancreatic microbiota of the subject, and/or (ii) inhibit growth and/or activity of one or more strains of bacteria from one or more species selected from the group consisting of Bacteroides acidifaciens, Bifidobacterium animalis, Bifidobacterium pseudolongum, Desulfovibrio D168 , Elizabethkingia meningoseptica, Escherichia coli, Mucispirillium schaedleri, Oxalobacter formigenes, Parabacteroides distasoni, Peptostreptococcus anaerobius, Prevotella melaninogenica, Prevotella stercorea, Pyramidobacter piscolens, Rothia mucilaginosa, Streptococcus anginosus , and Veillonella dispar in the gastrointestinal (GI) microbiota of the subject.
5. The method of claim 4 , wherein the one or more compounds and/or compositions comprise an antibiotic or natural product that inhibits microbial growth.
6. The method of claim 1 , wherein said one or more probiotic composition(s) are administered by a route selected from the group consisting of oral, rectal, sublingual, intravenous, and via naso/oro-gastric gavage.
7. The method of claim 1 , further comprising administering an additional cancer therapy.
8. The method of claim 7 , wherein the additional cancer therapy is selected from the group consisting of surgery, radiotherapy, chemotherapy, immunotherapy, and any combinations thereof.
9. The method of claim 1 , wherein said one or more probiotic compositions are administered directly to the pancreatic microbiota.
10. The method of claim 1 , wherein the pancreatic cancer is pancreatic ductal adenocarcinoma (PDA).
11. The method of claim 1 , wherein the subject is human.
12. The method of claim 1 , said method further comprising administering to the subject an effective amount of one or more probiotic compositions comprising one or more strains of bacteria from one or more species selected from the group consisting of Bifidobacterium pseudolongum, Faecalibacterium prausnitzii, Propionibacterium acnes, Bacteroides eggerthii, Blautia producta, Candidatus arthromitus, Eubacterium biforme, Faecalibacterium prausnitzii, Lactobacillus ruminis , and TM7.
13. The method of claim 1 , wherein the method comprises administering to the subject an effective amount of one or more antibiotics and/or natural products that inhibits microbial growth, prior to administering to the subject said one or more probiotic compositions.
14. The method of claim 1 , wherein the method does not comprise administering to the subject a prebiotic.